Literature DB >> 1657606

The molecular action of tumor necrosis factor-alpha.

G Camussi1, E Albano, C Tetta, F Bussolino.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a polypeptide hormone newly synthesized by different cell types upon stimulation with endotoxin, inflammatory mediators (C5a anaphylatoxin), or cytokines such as interleukin-1 and, in an autocrine manner, TNF itself. The net biological effect of TNF-alpha may vary depending on relative concentration, duration of cell exposure and presence of other mediators which may act in synergism with this cytokine. TNF-alpha may be relevant either in pathological events occurring in cachexia and endotoxic shock and inflammation or in beneficial processes such as host defense, immunity and tissue homeostasis. The biological effects of TNF-alpha are triggered by the binding to specific cell surface receptors. The formation of TNF-alpha-receptor complex activates a variety of biochemical pathways that include the transduction of the signal at least in part controlled by guanine-nucleotide-binding regulatory proteins (G proteins), its amplification through activation of adenyl cyclase, phospholipases and protein kinases with the generation of second messenger pathways. The transduction of selected genes in different cell types determines the characteristics of the cell response to TNF-alpha. The full understanding of the molecular mechanisms of TNF-alpha will provide the basis for a pharmacological approach intended to inhibit or potentiate selected biological actions of this cytokine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657606     DOI: 10.1111/j.1432-1033.1991.tb16337.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  58 in total

1.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.

Authors:  I A El-Ghrably; H S Dua; G M Orr; D Fischer; P J Tighe
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Fibrodynamics-elucidation of the mechanisms and sites of liver fibrogenesis.

Authors:  Catherine H Wu
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 3.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

4.  Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy.

Authors:  G A Limb; A H Chignell; W Green; F LeRoy; D C Dumonde
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

Review 5.  Inflammation and rheumatoid arthritis.

Authors:  Amit Kumar Shrivastava; Aparna Pandey
Journal:  J Physiol Biochem       Date:  2012-10-31       Impact factor: 4.158

6.  Listeriosis in patients receiving biologic therapies.

Authors:  M Bodro; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-09       Impact factor: 3.267

7.  Thiol modulation of TNF alpha and IL-1 induced MnSOD gene expression and activation of NF-kappa B.

Authors:  K C Das; Y Lewis-Molock; C W White
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

8.  Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation.

Authors:  O M Howard; K A Clouse; C Smith; R G Goodwin; W L Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Two distinct regions in the 3' untranslated region of tumor necrosis factor alpha mRNA form complexes with macrophage proteins.

Authors:  Z Hel; E Skamene; D Radzioch
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

10.  Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.

Authors:  Jean-Luc Davignon; Jean-Frédéric Boyer; Bénédicte Jamard; Delphine Nigon; Arnaud Constantin; Alain Cantagrel
Journal:  Arthritis Res Ther       Date:  2010-07-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.